Dataset Information


The miR-17?92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.

ABSTRACT: Mixed lineage leukemias have a relatively poor prognosis and arise as a result of translocations between the MLL(KMT2A) gene and one of multiple partner genes. Downstream targets of MLL are aberrantly upregulated and include the developmentally important HOX genes and MEIS1, as well as multiple microRNAs (miRNAs), including the miR-17?92 cluster. Here we examined the contribution of specific miRNAs to MLL leukemias through knockdown studies utilizing custom anti-microRNA oligonucleotides. Combinatorial treatment against miR-17-5p and miR-19a-3p of the miR-17?92 cluster dramatically reduces colony forming ability of MLL-fusion containing cell lines relative to non-MLL acute myeloid leukemia (AML) controls. To determine the mechanism by which these miRNAs contribute to leukemia, we validated PKNOX1 as a target of both miR-17-5p and miR-19a-3p. MEIS1 and PKNOX1 are TALE domain proteins that participate in ternary complexes with HOX and PBX partners. Here we establish the competitive relationship between PKNOX1 and MEIS1 in PBX-containing complex formation and determine the antagonistic role of PKNOX1 to leukemia in a murine MLL-AF9 model. These data implicate the miR-17?92 cluster as part of a regulatory mechanism necessary to maintain MEIS1/HOXA9 -mediated transformation in MLL leukemia, indicating that targeting multiple non-homologous miRNAs may be utilized as a novel therapeutic regimen.


PROVIDER: S-EPMC4899285 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3480215 | BioStudies
2012-01-01 | S-EPMC3342453 | BioStudies
1000-01-01 | S-EPMC2840429 | BioStudies
2012-01-01 | S-EPMC3511140 | BioStudies
2016-01-01 | S-EPMC4960006 | BioStudies
1000-01-01 | S-EPMC3973221 | BioStudies
1000-01-01 | S-EPMC1271748 | BioStudies
2015-01-01 | S-EPMC4537828 | BioStudies
2020-01-01 | S-EPMC7211762 | BioStudies
1999-01-01 | S-EPMC84099 | BioStudies